London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I posted the following on 21.06, reproduced here as it is directly relevant to the mobile testing conversation:
The q32 is £12,154, and would be preferable to the q16 in terms of capacity when used in a mobile application.
French distributor Atothis:
"Novacyt is working on other innovations to support laboratories during the pandemic. Exsig ™ Direct is an innovative and patented RNA extraction reagent that eliminates the need for complex and automated magnetic extraction systems. Exsig ™ Mag is Novacyt's magnetic bead-containing RNA extraction reagent for laboratories wishing to continue using their automated RNA extraction systems. The COVID-19 mobile test solution is a combination of Exsig ™ Direct reagents and the COVID-19 test optimized to work with the company's proprietary q16 and q32 instruments. The two Exsig ™ extraction reagents will be launched in June 2020 and the COVID-19 mobile system in July 2020."
note the "q16 and q32 instruments".
I asked the company via chat facility on Friday 20th June:
"Can you please advise whether the q16 instrument is solely recommended for mobile use, and not the q32 please, or is both recommended for mobile use?"
"We would generally recommend the q16 for mobile use.
The q32 is smaller enough for this role also, however is heavier than the q16 which makes it a bit more difficult to carry around."
However, - Achilleas Neophytou - Group Marketing Manager provided a "commercially sensitive information" response to my question regarding suitability of q32 for mobile use.
IMO that means we are still testing the mobile use of a q32 instrument, but I don't think tests will take much longer, and we will know whether it's q16 AND q32.
From the annual report (Page 21)
• Mobile COVID-19 testing is being evaluated using the
Company’s q16 instrument combined with its ExsigTM Direct
reagent. Trials in clinical laboratories are expected to complete
by the end of July 2020 and, subject to validation, this
combination will initially be used in remote locations, such as
The last line of my post should read:
Still looking, but I have not found any company that offers
" multiplex test to identify 37 respiratory pathogens"
EXMEX, - Have been looking hard for this US customer, because I thought they might be the US sales partner, but so far with no success.
From your link and clicking the Respiratory Panel option, the following text appears:
"Respiratory Panel enables rapid and accurate automated detection of pathogens behind respiratory infections. It tests for 17 viruses and 3 bacteria which cause upper respiratory tract infections."
The 07.10.2019 RNS (New molecular respiratory panel ready for the US market):
"Primerdesign has designed the multiplex test to identify 37 respiratory pathogens, which makes it one of the most comprehensive respiratory panels available in the market today."
So I don't agree Genesis is the customer.
Still looking, but I have not found any company that offers
"tests for 17 viruses and 3 bacteria which cause upper respiratory tract infections."
At January 2020 Novacyt had about 58m shares in issue, this has increased to approximately 72 million, an increase of over 20% of total shares. So an additional circa 13+ million novacyt shares have come to market in this short time. This has allowed all debt to be removed and approx 2 million of cash to be added to the cash balance through warrants. As a lot of these shares have been issued at strike prices at hugely reduced values compared to the current and recent share price, there was bound to be a lot of volatility. I would imagine a huge proportion of these shares are now disseminated to much longer holders of Novacyt stock. Most companies SP would have dropped hugely during this period but Novacyt's SP is still well above the prices from February 2020. The company have now been transformed into another complete different entity now with new products, updated machines, huge increases in new staff, agreements for manufacturing and outlets for sales, turnover anticipated to have increased over 20 times its 2019 sales. Novacyt have transformed themselves, at break neck speed, to become a hugely profitable company in what has been a transformational 6 months. There will be ups and downs along the way but Novacyt are now in a completely different sphere than as recently as January this year. To those that have bought higher and sitting on paper losses I hope that as more sales and accounts information are released the SP will find the true value we believe the stock should be taking into account the fundamentals and future income and profitability. I have 90% of my isa and sipp in novacyt so I am anticipating huge returns in the following few months and hopefully, and more importantly Novacyts tests and no how can have a huge effect in reducing Coronavirus. I think Novacyt should be up for business of the year award.
They do indeed EXMEX thanks for that info
Below is the pdf
ChasPB ,as far as I can find out Genesis Diagnostics are the US company that Novacyt developed the respiratory test panel for .They were named when this project was first announced in the rns on 27/11/18. Looking on their website there is only one respiratory test panel shown.
They also offer a 99 dollar covid19 test service using the primer design test.
At the end of the document
"During January and February 2020 Novacyt’s share price increased to over €2 per share, a key contributing factor being the launch of a Covid-19 diagnostic test kit by Primerdesign. This share price increase resulted in all remaining warrant holders exercising their warrants which gave rise to a net cash inflow of €2,400,000 into the business and the warrant overhang has now been removed completely."
The table for the warrants can be found on page 46
[[ would be good to have the company Clarify our involvement in USA ]]
from todays report:
Developments in the field of Molecular testing:
During the year, Primerdesign also completed the design and development of the molecular respiratory panel based
on a 384 well plate format for use by its North American business partner in their CLIA approved diagnostic testing
laboratory network. Primerdesign designed the multiplex test to identify 37 respiratory pathogens, which makes it
one of the most comprehensive respiratory panels available in the market today.
Primerdesign will supply this product under a five-year manufacturing agreement as its partner launches the new
respiratory panel in the US market through its own clinical testing laboratories to provide a Laboratory Developed
Diagnostic Test (“LDT”) result for its customers.
Let's not forget how far this company has come some other UK competitors were around 6 weeks or so behind us and they are still to produce or sell a single test.
For context consider the February RNS which hopefully should lift spirits. Which other company can claim such massive growth (and continuing) in 4 months! NCYT is also at the same time supporting the UK diagnostic market which the government early on in the crisis said was underdeveloped. From the bb there was the story of the last company to assist us with producing these tests and NCYT provided them with the lifeline to continue! From 40000 order in Feb to over £120 million let's not forget that achievement!
Mon, 17th Feb 2020 12:30
RNS Number : 2316D
17 February 2020
("Novacyt", the "Company" or the "Group")
Launch of CE-IVD Marked
novel coronavirus test
Paris, France and Camberley, UK - 17 February 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that its molecular diagnostics division, Primerdesign, has launched its CE-Mark molecular test for the clinical detection of the novel coronavirus (COVID-19).
The Directors believe that Primerdesign's COVID-19 test is the first CE-Mark test for the 2019 strain of novel coronavirus and follows the Company's rapid launch of its research use only (RUO) coronavirus test on 31 January 2020. As a result of the CE-Mark, the Company's COVID-19 test can be used directly by laboratories and hospitals for the testing of patients without the need for validation by clinicians. The Company anticipates increased demand for its test for COVID-19 due to this extended use for clinical diagnosis.
Primerdesign has already received requests for quotations for 288,000 CE-Mark tests since they were made available to pre-order on 14 February 2020. The Company has received orders for 40,000 RUO tests and requests for quotations for an additional 35,000 RUO tests prior to the launch of the COVID-19 clinical version. Demand for the tests has come from China, the US and the UK, as well as many other countries around the world.
The Company continues to see a high conversion rate from quotations to orders. However, it is difficult to predict how demand for the test will grow as the epidemic is still in its early stages. Since the initial reports of COVID-19, the Company has invested in manufacturing capacity to meet the current and potential future demand for its tests.
The Primerdesign test is being formally evaluated by public health authorities from five countries and the Company is in discussions with these organisations to potentially support their national screening requirements for COVID-19.
As previously announced, the Company has submitted an application to, and remains in discussion with, the US Food and Drug Administration (FDA)
strong buying again
did not think to many were prepared to stay out to long today if news is released
is there any who is not thinking news likely one day this week
From the management report
Manufacturing (more than 10 million)
The Company quickly established the need to develop significant
manufacturing capacity and today has eight dedicated manufacturing sites capable of producing COVID-19 tests
at an output rate of more than ten million tests per month, which Novacyt expects to achieve from June 2020
onwards. Through its investment in raw materials and manufacturing, the Company is now in a position to service
significant and expected growth in demand for its COVID-19 test.
The q32 provides test results within 60 minutes using genesig® kits, making it one of the fastest qPCR instruments
on the market due to its rapid heating and cooling capabilities and unique lid design